Have a question
Leading the Evolution of Heart Assist Devices
QHeart Medical Pty Ltd is an Australian privately owned, clinical stage MedTech company exploring the clinical utility of a novel “pumpless” heart assist device to address unresolved clinical consequences of heart failure, focused initially on the treatment of acute decompensated heart failure (ADHF).
QHeart Medical recently achieved proof of concept for its Transcatheter Aortic Recoil Repair (TARR™) implant, an endovascular intra-aortic balloon device, achieving significant improvement in blood flow from the heart.
The next step is to execute a pilot first-in-man study, before progressing to a clinical trial aiming to secure FDA clearance for the device.
To date, the project has been financed by a competitive grant (CRC Project Grant) and founders to a total of AU$10M.
To facilitate next steps, QHeart Medical is progressing a Capital Raise to fund an FDA clinical trial of the TARR™ device for use in the treatment of Acute Decompensated Heart Failure (ADHF).
QHeart Medical Pty Ltd is an Australian privately owned, clinical stage MedTech company exploring the clinical utility of a novel “pumpless” heart assist device to address unresolved clinical consequences of heart failure, focused initially on the treatment of acute decompensated heart failure (ADHF).
© QHeart Medical Pty Ltd, All rights reserved | Designed & Developed By Crafted Campus